Home/SolasCure/David Fairlamb

DF

David Fairlamb

Chief Development Officer

Therapeutic Areas

Wound Care Dermatology

SolasCure Pipeline

Drug	Indication	Phase
Aurase Wound Gel	Chronic Wounds (e.g., Venous Leg Ulcers, Diabetic Foot Ulcers)	Phase 2

Leadership Team at SolasCure

Chief Executive Officer

Andy Weymann, MD

Dr. Bela Kelety

Chief Technology Officer

Oliver Schofield

Chief Financial Officer

Antoinette van Dijk, MD

Director Clinical and Medical Affairs

View full SolasCure profile